Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency

Disease-causing mutations in the XIAPBIR2 domain impair NOD2-dependent immune signalling

(2013) Rune Busk Damgaard et al.   EMBO Molecular Medicine

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function

(2013) Madhusudhanan Sukumar et al.   JOURNAL OF CLINICAL INVESTIGATION

Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch

(2013) Patrick M Gubser et al.   NATURE IMMUNOLOGY

The PI3K/Akt/mTOR Pathway Is Implicated in the Premature Senescence of Primary Human Endothelial Cells Exposed to Chronic Radiation

(2013) Ramesh Yentrapalli et al.   PLoS One

mTOR, linking metabolism and immunity

(2013) Xiaojin Xu et al.   SEMINARS IN IMMUNOLOGY

mTOR and metabolic pathways in T cell quiescence and functional activation

(2013) Kai Yang et al.   SEMINARS IN IMMUNOLOGY

Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K

(2012) Mary Ellen Conley et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+T cells

(2012) David K. Finlay et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Signal Integration by Akt Regulates CD8 T Cell Effector and Memory Differentiation

(2012) E. H. Kim et al.   JOURNAL OF IMMUNOLOGY

PI3K-PKB/Akt Pathway

(2012) B. A. Hemmings et al.   Cold Spring Harbor Perspectives in Biology

Activation of mTORC2 by Association with the Ribosome

(2011) Vittoria Zinzalla et al.   CELL

Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega

(2011) F. Sievers et al.   Molecular Systems Biology

Second messenger role for Mg2+ revealed by human T-cell immunodeficiency

(2011) Feng-Yen Li et al.   NATURE

AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy

(2011) M V Astle et al.   ONCOGENE

Molecular Pathogenesis of EBV Susceptibility in XLP as Revealed by Analysis of Female Carriers with Heterozygous Expression of SAP

(2011) Umaimainthan Palendira et al.   PLOS BIOLOGY

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

B cell–intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans

(2010) Danielle T. Avery et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors

(2010) Alex Berndt et al.   Nature Chemical Biology

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE

Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110  and are disrupted in oncogenic p85 mutants

(2009) H. Wu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A frequent kinase domain mutation that changes the interaction between PI3K  and the membrane

(2009) D. Mandelker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking

(2008) Linda V Sinclair et al.   NATURE IMMUNOLOGY

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE

Helical domain and kinase domain mutations in p110  of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

(2008) L. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA